THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF UNITED KINGDOM DOMESTIC LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

14 April 2025

Ananda Pharma plc
("Ananda" or the "Company")

Ananda Pharma Shares to commence trading today in the U.S. on the OTCQB Exchange

Ananda Pharma plc (AQSE:ANA), a UK-based biopharmaceutical company developing regulatory approved, cannabinoid medicines to treat complex, chronic conditions, is pleased to announce that trading in the Company's ordinary shares of nominal value £0.002 each ("Ordinary Shares") will commence today, at 2.30 p.m. (London time)/9.30 a.m. (Eastern Standard Time) on the OTCQB Venture Market ("OTCQB") in the United States of America ("US").

The Ordinary Shares will trade on OTCQB under the ticker "ANANF".

Ananda's OTCQB information can be found on the OTC Markets website: https://www.otcmarkets.com/stock/ANANF/overview.

There is no associated capital raise with this cross trade and the Ordinary Shares will continue to trade on the Company's primary listing market, the Apex segment of the Aquis Stock Exchange ("AQSE") under the ticker "ANA".

Cross trading on OTCQB allows the Company to access one of the world's largest investment markets to expand its reach into a broader pool of investors and build brand awareness in the most important pharmaceutical market in the world. The Ordinary Shares will be available to US investors during US working hours and priced in US Dollars and should lead to easier cross-border trading for potential US investors. Further information about OTCQB can be found at: https://www.otcmarkets.com/learn/market-101.

For more information on Ananda Pharma and to watch a video about the OTCQB admission, head the Company's Hub: https://investors.anandapharma.co.uk/link/NPwgnP

Ananda's Chief Executive Officer, Melissa Sturgess commented: "Following the recent appointment of Chris Tovey, the former COO of Nasdaq-listed GW Pharmaceuticals and Jazz Pharmaceuticals, and our engagement of Viridian Capital Partners in New York, the OTCQB listing is the third step of our US strategy. As we start our world-leading cannabinoid clinical trials into a range of complex chronic conditions, we are focused on the US as the key market for commercializing future regulatory approved medicines. Increasing our visibility in this market is a crucial step and one I'm pleased we are making." 

For the purposes of UK MAR, the directors of the Company accept responsibility for the contents of this announcement.

- Ends -

Enquiries:

About Ananda Pharma plc

Ananda Pharma plc (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved, cannabinoid medicines to treat complex, chronic conditions, including epilepsy (trials funded by NHS England and NIHR), endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR). The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh, Great Ormond Street Hospital for Children and University College London.

To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels at:

·             Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93

·             Instagram: https://www.instagram.com/anandapharmaplc/

·             LinkedIn: https://www.linkedin.com/company/anandapharma

·             X: https://twitter.com/AnandaPlc

·             Investor Meet Company: https://www.investormeetcompany.com/ananda-pharma-plc/register-investor